Multiple Companies

 
News Articles for Multiple Companies top ^
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced its partnership with the National Multiple Sclerosis Society, Lone Star Chapter, as a sponsor of the nonprofit’s annual Houston area Walk MS fundraisers for the fourth consecutive year.
Sign-up for Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS investment picks
2014/10/15
Living with a chronic condition like multiple sclerosis (MS) can be overwhelming for individuals and caregivers who have to balance the challenges of everyday life and work while juggling regular doctors’ visits and medications.
Sign-up for Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals investment picks
- Selinexor Demonstrates Synergy in Combination with Approved Therapies for Multiple Myeloma - NEWTON, Mass., Dec.
Sign-up for Karyopharm Presents Positive Combination Data for Selinexor (KPT-330) in Multiple Myeloma Patients at ASH 2014 Annual Meeting investment picks
Alberta funds treatment with AUBAGIO® for Relapsing Remitting Multiple Sclerosis Canada NewsWire MISSISSAUGA, ON , Dec.
Sign-up for Alberta funds treatment with AUBAGIO® for Relapsing Remitting Multiple Sclerosis investment picks
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis Canada NewsWire MISSISSAUGA, ON , Nov.
Sign-up for Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis investment picks
5N Plus Winner in Multiple Categories in the 2014 Deloitte Technology Fast 50™ Awards for a Fifth Consecutive Year Canada NewsWire MONTRÉAL, Nov.
Sign-up for 5N Plus Winner in Multiple Categories in the 2014 Deloitte Technology Fast 50™ Awards for a Fifth Consecutive Year investment picks
2014/11/27
RBC Global Asset Management Inc. Receives Multiple Distinctions at 2014 Morningstar Awards Canada NewsWire TORONTO , Nov.
Sign-up for RBC Global Asset Management Inc. Receives Multiple Distinctions at 2014 Morningstar Awards investment picks
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Overall Response Rate, Duration of Response, Health-Related Quality of Life Secondary Endpoints Met; Overall Survival Continues to be Monitored Results to be Presented During an Oral Session at ASH on Sunday, December 7 at 12 p.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 8 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma investment picks
2014/12/5
Air Canada Wins Multiple Travel Awards Affirming its Leadership Position among North American Carriers Canada NewsWire Awarded 'Best Airline in North America ' for 10th time MONTREAL , Dec.
Sign-up for Air Canada Wins Multiple Travel Awards Affirming its Leadership Position among North American Carriers investment picks
Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data demonstrating that its comprehensive genomic profile, FoundationOne® Heme , identified genomic alterations in patients with heavily pre-treated multiple myeloma that informed treatment with trametinib, an FDA-approved targeted therapeutic agent 1 .
Sign-up for Treatment for Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity investment picks
2014/12/12
RBC Global Asset Management Inc. Announces Management Fee Reductions for Multiple RBC Balanced Funds Canada NewsWire TORONTO , Dec.
Sign-up for RBC Global Asset Management Inc. Announces Management Fee Reductions for Multiple RBC Balanced Funds investment picks
British Columbia funds treatment with AUBAGIO™ for Relapsing Remitting Multiple Sclerosis Canada NewsWire MISSISSAUGA, ON , Dec.
Sign-up for British Columbia funds treatment with AUBAGIO™ for Relapsing Remitting Multiple Sclerosis investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced multiple regulatory milestones for Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, in the U.S. and European Union.
Sign-up for Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union investment picks
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today reviewed recent progress and announced upcoming milestones in its efforts to develop multiple combinations of medicines that treat the underlying cause of cystic fibrosis (CF) for the majority of people with the disease.
Sign-up for Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis investment picks
Executives from Cyan (NYSE: CYNI), a leading provider of SDN, NFV, and packet-optical solutions for network operators, will be presenting and participating in a panel on SDN and NFV, in addition to leading multiple live proof of concept demonstrations at the Layer123 SDN and OpenFlow World Congress in Düsseldorf, Germany from Oct.
Sign-up for Cyan to Showcase SDN and NFV Expertise with Multiple Presentations and Live Demonstrations at Layer123 SDN and OpenFlow World Congress investment picks
2014/10/13
Program allows MLS to send real-time listings directly to Zillow on behalf of participating brokerages SEATTLE , Oct.
Sign-up for New Jersey Multiple Listing Service, Inc. Joins Zillow Partnership Platform investment picks
Genzyme , a Sanofi company, announced today enrollment of the first patient in a multicenter Phase II clinical trial to evaluate Genzyme’s investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS). The trial, called EMPIRE, is designed to assess the efficacy of vatelizumab vs.
Sign-up for Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis investment picks
SiriusXM Announces exclusive Halloween programming to air across multiple talk, music, and comedy channels Canada NewsWire TORONTO , Oct.
Sign-up for SiriusXM Announces exclusive Halloween programming to air across multiple talk, music, and comedy channels investment picks
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a paper, titled “PYK2 Promotes Tumor Progression in Multiple Myeloma,” has been published in Blood (2014 Oct 23;124(17):2675-86), a peer-reviewed medical journal published by the American Society of Hematology.
Sign-up for Scientific Data on PYK2 Inhibition by VS-4718 in Multiple Myeloma Published in the Journal Blood investment picks
RedoxSYS Diagnostic System Utilized in Studies of Parkinson's Disease, Multiple Sclerosis, and Exercise-Induced Oxidative Stress in Athletes ENGLEWOOD, Colo.
Sign-up for Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Multiple Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Multinational Companies  |  Next: Multiple Managers